Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Financial Performance - Aurinia Pharmaceuticals reported fourth-quarter earnings of $0.01 per share, an improvement from a loss of $0.19 per share a year ago and better than the consensus loss of $0.02 [1] - Fourth-quarter sales reached $59.9 million, reflecting a 33% year-over-year increase, aligning with the consensus estimate [1] - For the full year 2024, net product sales were $216.2 million, up 36%, within the management guidance of $210 million to $220 million [2] - The company reported an operating loss of $1.67 million, significantly reduced from a loss of $29.7 million in the previous year [2] - Aurinia achieved a net income of $1.43 million, a notable improvement from a loss of $26.9 million [2] Product Performance - Net product sales of LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis, amounted to $57.6 million, marking a 36% increase [4] - License, collaboration, and royalty revenue, which includes manufacturing services revenue and royalties from collaboration partner Otsuka, totaled $2.3 million, down 18% [4] Future Outlook - The CEO of Aurinia anticipates 2025 to be a pivotal year for increasing the adoption of LUPKYNIS and advancing AUR200, which has potential applications in treating various autoimmune diseases [3] - The company expects fiscal year revenue guidance of $250 million to $260 million, compared to the consensus estimate of $274.4 million [3] Stock Performance - Following the earnings report, Aurinia's stock declined by 6.35%, trading at $7.45 [3]